EULAR 2025

What about malignancies with JAKi treatment?

Interfering on the long run: less difficult-to-treat pts. after 1st line anti-TNF in early RA?

Preventing, delaying or early sufficient treatment of RA?

Benefit of MTX underpinned in newly diagnosed PMR!

Cardiovascular impact of GLP-1 receptor agonists in patients with AS

IL-17A/IL-17F-inhibiting nanobody as a new molecule in PsA

Real world data of Adalimumab vs Ixekizumab in PsA

TYK2-Inhibitors a new oral treatment option?

Cardiovascular impact of GLP-1 receptor agonists in patients with AS

New bispecific antibodies against axSpA?

Impact of biologics on cardiovascular outcome in AS

Subjective or objective endpoints - is there a preference?

Impact of GLP-1 receptor agonists on cardiovascular events in AS

The IL-17 story continues!

Sex-specific response on biologics

Effect of TNF inhibitors on the risk of cancer recurrence in AS

Connection between pain and disease activity

Cancer reactivation in axSpA patients treated with TNF-blocker

Krebs-Reaktivierung bei mit TNF-Blockern behandelten axSpA-Patienten

Die IL-17-Story geht weiter!

Neue bispezifische Antikörper gegen axSpA?

Impatto dei farmaci biologici sugli esiti cardiovascolari nella spondilite anchilosante (AS)

Zusammenhang von Schmerz und Krankheitsaktivität

Impatto degli agonisti del recettore GLP-1 sugli eventi cardiovascolari nella spondilite anchilosante (AS)

Effetti degli inibitori del TNF sul rischio di recidiva di cancro nella spondilite anchilosante (AS)

Geschlechtsspezifisches Ansprechen auf Biologika

Subjektive oder objektive Endpunkte - gibt es eine Präferenz?

TYK2-Inhibitors a new oral treatment option?

IL-17A/IL-17F-inhibiting nanobody as a new molecule in PsA

Real world data of Adalimumab vs Ixekizumab in PsA

TYK2 inhibitors in PsA

IL-23 stops radiographic progress

Definitions and prevalence of difficult-to-treat PsA

Sonelokimab, a novel IL-17A- and IL-17F-inhibiting nanobody, demonstrates strong efficacy

Hit hard & early or tight control - two ways to reach the goal

Sonelokimab - again IL-17 inhibition or new IL-17 inhibition?

Difficult-to-treat patients in active PsA

Sexual health in patients with PsA

MTX+LEF strategy vs MTX alone in PsA

High prevalence of PsA in PsO patients without musculoskeletal symptoms

TYK2: convenient, safe and effective!

Stratégie MTX+LEF vs MTX seul dans le rhumatisme psoriasique

Difficult-to-treat patients in active PsA

Hohe Prävalenz von PsA bei PsO-Patienten ohne muskoskelettale Symptome

Sonelokimab - schon wieder IL-17-Inhibition oder neue IL-17-Inhibition?

IL-23 stoppt radiografischen Progress

TYK2: bequem, sicher und auch wirksam!

Definición y prevalencia de la APs difícil de tratar

TYK2-Inhibitoren bei PsA

Santé sexuelle au cours du rhumatisme psoriasique

Hit Hard & Early oder Tight Control - zwei Wege zum Ziel

Sonelokimab, a novel IL-17A- and IL-17F-inhibiting nanobody, demonstrates strong efficacy

Preventing, delaying or early sufficient treatment of RA?

What about malignancies with JAKi treatment?

Interfering on the long run: less difficult-to-treat pts. after 1st line anti-TNF in early RA?

Cancer incidence in RA from the JAK-POT study

Cancer risk under biologic therapy in RA

Safety of JAKies in RA

Prophylactic therapy with abatacept in patients at risk of RA

New treatment options in RA

Abatacept in individuals at risk of delevoping RA

ILD in rheumatoid arthritis

Cancer incidence in RA from the JAK-POT study

Prophylaktische Therapie mit Abatacept bei Patienten mit RA-Risiko

Risque de cancer sous biomédicament dans la PR

Abatacept en individuos en riesgo de desarrollar AR

Benefit of MTX underpinned in newly diagnosed PMR!

Benefit of MTX underpinned in newly diagnosed PMR

Benefit von MTX bei neu diagnostizierter PMR untermauert

Cardiovascular outcomes of treat-to-target urate-lowering treatment in gout

Desenlaces cardiovasculares del tratamiento por objetivos de la uricemia en gota

Cancer mortality in inflammatory joint diseases

Cost-effectiveness of therapeutic drug monitoring

Patient history matters: real-world data of infliximab biosimilar

New therapeutic approach for refractory myositis

Combination therapies in immune mediated inflammatory diseases

Neuer Therapieansatz für refrakträre Myositis

Cancer mortality in inflammatory joint diseases

Die Patientengeschichte zählt: Infliximab-Biosimilar Real-World Daten

Kombinationstherapien bei immunvermittelten entzündlichen Erkrankungen

Cost-effectiveness of therapeutic drug monitoring